MX2022007681A - Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de tipo hepatitis b. - Google Patents

Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de tipo hepatitis b.

Info

Publication number
MX2022007681A
MX2022007681A MX2022007681A MX2022007681A MX2022007681A MX 2022007681 A MX2022007681 A MX 2022007681A MX 2022007681 A MX2022007681 A MX 2022007681A MX 2022007681 A MX2022007681 A MX 2022007681A MX 2022007681 A MX2022007681 A MX 2022007681A
Authority
MX
Mexico
Prior art keywords
methods
heteroaryldihydropyrimidine
infections
derivatives
treating hepatitis
Prior art date
Application number
MX2022007681A
Other languages
English (en)
Inventor
Zhanling Cheng
Zhiguo Liu
Yimin Jiang
Linglong Kong
Jianping Wu
Yanping Xu
Gang Deng
Chao Liang
Xiangjun Deng
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022007681A publication Critical patent/MX2022007681A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan compuestos útiles para el tratamiento de la infección por VHB en un sujeto que lo necesite, composiciones farmacéuticas de estos y métodos para inhibir, suprimir o prevenir la infección por VHB en el sujeto.
MX2022007681A 2019-12-20 2020-12-18 Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de tipo hepatitis b. MX2022007681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019127038 2019-12-20
PCT/CN2020/137480 WO2021121363A1 (en) 2019-12-20 2020-12-18 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections

Publications (1)

Publication Number Publication Date
MX2022007681A true MX2022007681A (es) 2022-07-19

Family

ID=76476698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007681A MX2022007681A (es) 2019-12-20 2020-12-18 Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de tipo hepatitis b.

Country Status (10)

Country Link
US (1) US20230002408A1 (es)
EP (1) EP4077305A4 (es)
JP (1) JP2023506528A (es)
KR (1) KR20220119666A (es)
CN (1) CN114867717A (es)
AU (1) AU2020404317A1 (es)
BR (1) BR112022011212A2 (es)
CA (1) CA3160543A1 (es)
MX (1) MX2022007681A (es)
WO (1) WO2021121363A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
HUE034919T2 (en) * 2012-08-24 2018-03-28 Sunshine Lake Pharma Co Ltd 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives such as hepatitis B virus (HBV) polymerase inhibitors, for example, for the treatment of chronic hepatitis
CN103664897B (zh) * 2012-09-01 2018-04-03 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
JP6533217B2 (ja) * 2013-05-17 2019-06-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類
CN104650069B (zh) * 2013-11-19 2019-04-19 广东东阳光药业有限公司 4-甲基二氢嘧啶类化合物及其在药物中的应用
CA2935811C (en) * 2014-03-07 2018-09-18 F. Hoffmann-La Roche Ag 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN109689059A (zh) * 2016-08-24 2019-04-26 豪夫迈·罗氏有限公司 Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法
US11142527B2 (en) * 2017-06-26 2021-10-12 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine

Also Published As

Publication number Publication date
EP4077305A4 (en) 2024-01-10
CA3160543A1 (en) 2021-06-24
CN114867717A (zh) 2022-08-05
AU2020404317A1 (en) 2022-08-11
EP4077305A1 (en) 2022-10-26
JP2023506528A (ja) 2023-02-16
BR112022011212A2 (pt) 2022-09-20
US20230002408A1 (en) 2023-01-05
WO2021121363A1 (en) 2021-06-24
KR20220119666A (ko) 2022-08-30

Similar Documents

Publication Publication Date Title
MX2021007602A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
CR20230104A (es) Compuestos y métodos para el tratamiento de infecciones virales
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
MX2016009449A (es) Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb).
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
PH12019500083A1 (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
EP3833387A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRUS INFECTION
EP4121040A4 (en) METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE APPEARANCE OF A VIRAL INFECTION
MX2018011095A (es) Compuestos de carbapenem.
NZ737820A (en) Mannose derivatives for treating bacterial infections